Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2024
Reporting Period: Third Quarter ended September 30, 2024
This filing serves as a notification that the Company issued a press release announcing its results of operations and financial condition for the third quarter of 2024. Additionally, an updated corporate presentation was released to investors.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided text does not contain specific numerical values for revenue, net income, operating cash flow, margins, debt levels, or liquidity positions. These figures are contained within the referenced press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2), which are incorporated by reference but not included in the text of this 8-K.
Material Changes
The filing does not detail specific material changes in financial performance or operations compared to prior periods. It solely references the announcement of Q3 2024 results and the release of an updated corporate presentation.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard caution regarding forward-looking statements. These statements relate to anticipated performance under the "Tempus Agreement" and the "Restated Agreement," as well as other non-historical projections.
- Risks and Uncertainties: Management notes that actual results may differ materially from projections due to known and unknown risks, including those detailed in the "Risk Factors" section of the Company's most recent Form 10-K and subsequent Form 10-Q filings.
- Legal Disclaimer: Information furnished under Item 2.02 and Item 7.01 (including the press release and presentation) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly incorporated by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2024 financial results, including revenue, net loss, and cash burn rates.
- Examine Exhibit 99.2 (Corporate Presentation) for updated strategic outlook, pipeline progress, and guidance.
- Verify the terms and status of the Tempus Agreement and Restated Agreement mentioned in the forward-looking statements.
- Consult the most recent Form 10-K and Form 10-Q for a comprehensive list of risk factors affecting the Company's operations.